I[ntroduction]{.smallcaps} {#sec1-1}
==========================

*Acinetobacter* spp. are glucose-nonfermentative, nonmotile, nonfastidious, catalase-positive, oxidase-negative, aerobic Gram-negative coccobacilli. *Acinetobacter baumannii* has emerged as an important pathogen causing a variety of infections including pneumonia, bloodstream infections, skin and soft tissue infections, and urinary tract infections, resulting in high morbidity and mortality.\[[@ref1]\] Among the bacterial species monitored by the China Surveillance Program of Antimicrobial Resistance, *A. baumannii* was the third most common Gram-negative bacteria, just behind *Escherichia coli* and *Klebsiella pneumoniae*.\[[@ref2]\] *A. baumannii* was the fifth most common Gram-negative bacteria in the U.S. hospitals between 2006 and 2007.\[[@ref3]\] In recent years, due to the widespread use of broad-spectrum antibiotics, the rapid increase of drug resistance of *A. baumannii* has become an urgent issue around the world. In addition to its intrinsic resistance to many commonly used antibiotics, this pathogen can gain additional resistance rapidly in response to new broad-spectrum antibiotics.\[[@ref3]\] The emergence of multidrug resistance (MDR), extensive drug resistance (XDR), and even pan-drug resistance (PDR) is common among *A. baumannii* isolates.\[[@ref4]\] As a consequence, MDR, XDR, and PDR now present a significant challenge in the management of bacterial infections. For infections caused by drug-resistant strains, efficacious treatment is limited and therefore *A. baumannii* has become an important cause of nosocomial infections over the past 10 years.

M[ethods]{.smallcaps} {#sec1-2}
=====================

Study period and unit {#sec2-1}
---------------------

Between 2004 and 2014, 17--20 tertiary hospitals (17 hospitals in 2004--2005; 20 in 2007--2008; 19 in 2009--2010; 19 in 2011--2012; and 19 in 2013--2014), in economically developed, densely populated major cities in mainland China, participated in the China Surveillance of Antimicrobial Resistance Program. These hospitals are located in three regions of China: 8--11 in the eastern, three in central, and 4--7 in the western regions. Each participating hospital had two to four research unit wards, but only one Intensive Care Unit (ICU) ward for these studies was selected. The selected wards performed annual monitoring of all bacterial infections, as one bacteriological examination per collection year. The study period spanned from 2004 to 2014. Bacterial samples were collected biennially from these tertiary hospitals, for every year except 2006.

Bacterial isolates and information {#sec2-2}
----------------------------------

All samples were collected and identified in each tertiary hospital and forwarded to a central monitoring laboratory (Microbiology Laboratory, the Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China) for identification and susceptibility testing.

Any body site was considered an acceptable region to sample; however, sterile sites were sampled in preference, if possible (e.g., blood, pleural effusion, and cerebrospinal fluid). Only a single sample was permitted from each patient. Inclusion of any isolate in the study was independent of a patient\'s medical history, previous antimicrobial use, age, or gender. Ethics Committee approval was not required as the study does not collect patient-identifying information.

Antimicrobial susceptibility testing {#sec2-3}
------------------------------------

Minimum inhibitory concentrations (MICs) for all pathogens were determined using the Clinical Laboratory Standards Institute (CLSI) 2-fold agar dilution method.\[[@ref5]\] Piperacillin, piperacillin-tazobactam, ceftazidime, cefoperazone/sulbactam, cefepime, imipenem, amikacin, ciprofloxacin, levofloxacin, minocycline, tigecycline, and colistin were tested on all pathogen samples from each study year. Quality control strains were tested on each day of sample testing and included *E. coli* ATCC 25922 and ATCC 35218 and *Pseudomonas* aeruginosa ATCC 27853. Antimicrobial susceptibility phenotypes were established using CLSI-approved breakpoints. The CLSI 2014 version was used for all samples in this study.\[[@ref5]\]

Identification of extensive drug resistance *Acinetobacter baumannii* {#sec2-4}
---------------------------------------------------------------------

Bacterial isolates not susceptible to all the tested aminoglycosides, fluoroquinolones, β-lactams, β-lactam/β-lactam inhibitors, and carbapenems were defined as XDR. This is a modification of the European Centre for Disease Prevention and Control (ECDC) definition of XDR, which specified nonsusceptibility to at least one agent in all but two or fewer antimicrobial categories.\[[@ref4][@ref6]\] According to the CLSI 2014 version-approved breakpoints, extensively drug-resistant *A. baumannii* (XDRAB) screened out from all clinical strains were not susceptible to all the above-described antimicrobial agents.\[[@ref5]\]

R[esults]{.smallcaps} {#sec1-3}
=====================

Bacterial isolates {#sec2-5}
------------------

Between 2004 and 2014, a total of 2917 *A. baumannii* samples were collected. Isolates were mostly recovered from respiratory samples (1834 isolates, 62.9%), followed by blood (343, 11.8%), pus/discharge (293, 10.0%), excreta of wounds (229, 7.9%), and urine (118, 4.0%). Of these samples, 1800 (61.7%) were from non-ICU wards and 1117 (38.4%) were from ICU. Samples from the eastern region of China comprised the largest proportion of the total samples collected (1489, 51.0%) \[[Table 1](#T1){ref-type="table"}\].

###### 

Sources of *Acinetobacter baumannii* isolates included in the China Surveillance Program of Antimicrobial Resistance by year

  Strata              2004--2005   2007--2008   2009--2010   2011--2012   2013--2014   2004--2014
  ------------------- ------------ ------------ ------------ ------------ ------------ -------------
  Hospital region                                                                      
   Eastern (8--11)    254 (61.5)   243 (51.4)   459 (58.6)   264 (44.0)   269 (41.6)   1489 (51.0)
   Central (3)        82 (19.9)    52 (11.0)    128 (16.3)   90 (15.0)    125 (19.3)   477 (16.4)
   Western (4--7)     77 (18.6)    178 (37.6)   197 (25.1)   246 (41.0)   253 (39.1)   951 (32.6)
  Patient location                                                                     
   ICU                128 (31.0)   162 (34.2)   359 (45.8)   214 (35.7)   254 (39.3)   1117 (38.3)
   Non-ICU            285 (69.0)   311 (65.8)   425 (54.2)   386 (64.3)   393 (60.7)   1800 (61.7)
  Specimen type                                                                        
   Respiratory        355 (86.0)   388 (82.0)   565 (72.1)   266 (44.3)   260 (40.2)   1834 (62.9)
   Discharge          8 (1.9)      32 (6.8)     94 (12.0)    114 (19.0)   104 (16.1)   352 (12.1)
   Blood              9 (2.2)      27 (5.7)     99 (12.6)    70 (11.7)    138 (21.3)   343 (11.8)
   Excreta of wound   5 (1.2)      15 (3.2)     15 (1.9)     101 (16.8)   93 (14.4)    229 (7.8)
   Urine              13 (3.1)     5 (1.0)      8 (1.0)      42 (7.0)     50 (7.7)     118 (4.0)
   Others             23 (5.6)     6 (1.3)      3 (0.4)      7 (1.2)      2 (0.3)      41 (1.4)
                                                                                       
   Total              413 (100)    473 (100)    784 (100)    600 (100)    647 (100)    2917 (100)

All data were expressed as *n* (%). ICU: Intensive Care Unit.

Changes in nonsusceptibility to different antimicrobial agents over the years {#sec2-6}
-----------------------------------------------------------------------------

The rates of nonsusceptibility to different antimicrobial agents between 2004 and 2014 are shown in [Table 2](#T2){ref-type="table"}. The trend of nonsusceptibility to piperacillin/tazobactam, ceftazidime, cefepime, imipenem, amikacin, levofloxacin, minocycline, and colistin over the 10-year period is also shown in [Figure 1](#F1){ref-type="fig"} to highlight the rapid increase in imipenem (carbapenem) nonsusceptibility from 16.4% (MIC~90~ 8 mg/L) in 2004 to 71.4% (MIC~90~ 64 mg/L) in 2014. The rates of nonsusceptibility to other antimicrobial agents remained high (\>56.4%) over this time period although slight fluctuations were observed with some agents \[[Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}\]; nonsusceptibility to piperacillin/tazobactam, ceftazidime, cefepime, amikacin, and levofloxacin increased nonsignificantly, and then stayed at a plateau \[[Table 2](#T2){ref-type="table"}\]. In contrast, the rate of nonsusceptibility to minocycline increased significantly from 13.5% (MIC~90~ 8 mg/L) in 2004 to 64.5% (MIC~90~ 32 mg/L) in 2014. The rate of nonsusceptibility to colistin (not yet listed for sale in mainland China) increased slightly from 0.9% to 3.0% (MIC~90~ 1--2 mg/L) over a 6-year period.

###### 

Antibacterial susceptibility of *Acinetobacter baumannii* between 2004 and 2014

  Antibiotic      Year (isolates)                                                                                                                             
  --------------- ----------------- ------ ------ ----- ------ ------ ------ ----- ------ ------ ------ ----- ------ ------ ------ ----- ------ ------ ------ -----
  Piperacillin    12.6              10.4   77.0   512   8.2    23.9   67.9   512   20.3   8.0    71.7   512   17.3   7.0    75.7   512   13.0   10.3   76.7   512
  Pip/taz         25.9              30.3   43.8   256   29.6   29.2   41.2   512   27.2   9.8    63.0   512   24.2   4.3    71.5   512   24.3   0.9    74.8   512
  Ceftazidime     30.7              1.5    67.8   512   35.9   4.2    59.8   512   28.3   0.6    71.0   512   25.7   0.7    73.7   512   25.5   0.6    73.9   512
  Cfp/sub         --                --     --     64    --     --     --     32    --     --     --     64    --     --     --     128   --     --     --     128
  Cefepime        30.8              8.5    60.8   512   39.1   14.2   46.7   256   27.9   15.6   56.5   128   26.0   11.7   62.3   256   24.0   3.5    72.5   256
  Imipenem        83.5              3.1    13.3   8     63.2   4.2    32.6   64    42.2   2.0    55.7   64    33.2   1.5    65.3   64    28.6   0.9    70.5   64
  Amikacin        42.6              1.2    56.2   512   43.6   0.8    55.6   512   31.8   0.9    67.3   512   33.2   0.7    66.2   512   33.7   0.3    66.0   512
  Ciprofloxacin   38.5              0.5    61.0   64    33.8   1.7    64.5   64    28.2   0.6    71.2   128   23.8   0.2    76.0   64    24.7   0.0    75.3   128
  Levofloxacin    41.4              19.9   38.7   16    39.7   24.3   35.9   16    34.3   25.1   40.6   16    25.8   19.8   54.3   16    25.8   10.7   63.5   16
  Minocycline     86.5              8.2    5.3    8     87.5   7.8    4.7    8     73.3   17.5   9.2    8     58.7   18.7   22.7   16    35.5   23.8   40.7   32
  Tigecycline     --                --     --     ND    --     --     --     ND    --     --     --     4     71.0   --     --     --    49.8   --     --     4
  TMP/SMX         --                --     --     ND    --     --     --     ND    27.8   --     72.2   128   23.7   --     76.3   128   38.9   --     61.1   128
  Colistin        --                --     --     ND    --     --     --     ND    99.1   --     0.9    1     96.7   --     3.3    2     97.0   --     3.0    1

MIC: Minimum inhibitory concentrations; Pip/taz: Piperacillin/tazobactam; Cfp/sub: Cefoperazone/sulbactam; TMP/SMX: Trimethoprim/sulfamethoxazole; ND: Not deducted; --: Not available; S: Susceptible; I: Intermediate; R: Resistant.

![Trends in antimicrobial nonsusceptibility of *Acinetobacter baumannii* from 2004 to 2014.](CMJ-130-659-g001){#F1}

Cefoperazone/sulbactam is one of the most commonly used antimicrobials for the treatment of *Acinetobacter* spp. infections and is routinely used in China. This study also investigated the *in vitro* activity of cefoperazone/sulbactam (2:1) and found it to be superior to that of other third-generation cephalosporins alone against clinical isolates of *A. baumannii* (MIC~90~ 64--128 mg/L), in which activity is due to sulbactam alone \[[Table 2](#T2){ref-type="table"}\]. For the combination of cefoperazone/sulbactam, there are no standards specified by the CLSI or the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for the sulbactam concentration to be used in agar dilution or disk diffusion tests, and interpretations usually take into account the MICs of cefoperazone.

There are no CLSI and EUCAST breakpoints available for tigecycline (2011 in listed). However, over the past 6 years, the MIC~90~ of tigecycline was 4 mg/L.

Emergence of drug-resistant *Acinetobacter baumannii* {#sec2-7}
-----------------------------------------------------

The prevalence of XDRAB increased significantly from 11.1% in 2004 to 60.4% in 2014, with an overall prevalence rate of 43.7% (1276 samples) over the 10-year study period \[[Table 3](#T3){ref-type="table"}\]. The increase in XDRAB also occurred in samples from different specimen types, in ICU as well as non-ICU patients, and in different geographical regions of China from 2004 to 2014 \[Figures [2](#F2){ref-type="fig"}-[4](#F4){ref-type="fig"}\].

###### 

Relevant factors and prevalence of XDRAB from 2004 to 2014 in China

  Strata             2004--2005 (*n* = 413)   2007--2008 (*n* = 473)   2009--2010 (*n* = 784)   2011--2012 (*n* = 600)   2013--2014 (*n* = 647)   2004--2014 (*n* = 2917)
  ------------------ ------------------------ ------------------------ ------------------------ ------------------------ ------------------------ -------------------------
  Hospital region                                                                                                                                 
   Eastern           32 (12.6)                63 (25.9)                234 (51.8)               146 (55.3)               170 (63.2)               645 (43.5)
   Central           4 (4.9)                  7 (13.5)                 55 (43.0)                58 (64.4)                87 (69.6)                211 (44.2)
   Western           10 (13.0)                52 (29.2)                86 (42.2)                138 (56.1)               134 (53.0)               420 (43.8)
  Patient location                                                                                                                                
   ICU               14 (10.9)                38 (23.5)                202 (56.3)               153 (71.5)               201 (74.7)               608 (53.7)
   Non-ICU           32 (11.2)                84 (27.0)                173 (40.7)               189 (49.0)               190 (50.3)               668 (37.4)
  Specimens                                                                                                                                       
   Respiratory       36 (10.1)                97 (25.0)                261 (46.2)               150 (56.4)               155 (59.6)               699 (38.1)
   Blood             3 (33.3)                 8 (29.6)                 51 (51.5)                41 (58.6)                88 (63.8)                191 (55.7)
   Discharge         2 (25.0)                 13 (40.6)                55 (58.5)                79 (69.3)                66 (63.5)                215 (61.1)
   Others            5 (12.2)                 4 (15.4)                 8 (30.8)                 72 (48.0)                82 (56.6)                171 (44.1)
                                                                                                                                                  
   Total             46 (11.1)                122 (25.8)               375 (47.8)               342 (57.0)               391 (60.4)               1276 (43.7)

All data were expressed as *n* (%). *n*: Number of cases; XDRAB: Extensively drug-resistant *Acinetobacter baumannii*; ICU: Intensive Care Unit.

![Trends of extensive drug resistance rates in *Acinetobacter baumannii* by geographic region of China from 2004 to 2014.](CMJ-130-659-g002){#F2}

![Trends of extensive drug resistance rates in *Acinetobacter baumannii* by health-care setting in China from 2004 to 2014.](CMJ-130-659-g003){#F3}

![Trends of extensively drug resistance rates in *Acinetobacter baumannii* by sample origin from 2004 to 2014 in China. XDRAB: Extensively drug-resistant *Acinetobacter baumannii*.](CMJ-130-659-g004){#F4}

D[iscussion]{.smallcaps} {#sec1-4}
========================

This nationwide longitudinal study of 2917 *A. baumannii* samples over 10 years revealed the continuous increase of nonsusceptibility to antibiotics and the emergence of XDRAB. For most common antibiotics, the resistance rate of *A. baumannii* is maintained at a high level and increased slightly from 2004 to 2014. Minocycline is a derivative of tetracycline, but due to its toxicity, it is not a common antibiotic in hospitals in mainland China. However, the rate of nonsusceptibility to minocycline rapidly increased from 13.6% (with a resistance rate of 5.3%) to 64.5% (resistance rate of 40.7%) between 2004 and 2014, which was higher than that reported for the monitoring data between 2005 and 2011 (susceptible rate of 72.1%) by Denys *et al*.\[[@ref7]\]

Carbapenems are the main antibacterial agents used to treat serious infections, especially MDR infections. The increasing rate of resistance to carbapenems has raised a wide concern. In most cases, samples that are resistant to carbapenems are also resistant to many other types of antibiotics, which cause difficulties in clinical therapy and infection control. The prevalence rates of imipenem-resistant *A. baumannii* (IRAB) were 14.1%, 39.4%, 11.4%, and 30.8% in Europe, Latin America, North America, and the Asia-Pacific region, respectively, according to surveillance data from 2004 to 2006 reported by Reinert *et al*.\[[@ref8]\] Study data from Gales *et al*.\[[@ref9]\] in 2009 showed that the prevalence of IRAB was 54.9%, 76.3%, 37.5%, and 62.6% in Europe, Latin America, North America, and the Asia-Pacific region, respectively, and up to 59.8% worldwide. A monitoring report by the ECDC in 2013 showed that the prevalence of carbapenem-resistant *A. baumannii* was 3.6%, and the nonsusceptibility rate was 81.2%.\[[@ref9]\] Our research revealed that in mainland China, although the imipenem susceptibility rate was higher than that of other types of antibiotics, its nonsusceptibility rate had rapidly increased 4 folds during our 10-year study to an alarming 71.4% (resistance rate 70.5%), which was higher than the nonsusceptibility rate of amikacin (66.3%). Our survey data also revealed that the nonsusceptibility rate of IRAB was higher than that from other countries and similar to the imipenem resistance rates reported in China.\[[@ref10][@ref11]\]

In our study, the rate of resistance to colistin in 2009--2010, which has not been sold in mainland China yet, was only 0.9%, which was similar to that reported in samples from the Asia-Western Pacific region between 2006 and 2009.\[[@ref9]\] In contrast, one study in Korea reported a resistance rate of 18.1%.\[[@ref12]\] The rate of resistance to colistin in 2013--2014 had increased to 3.0% (MIC~90~ = 1 mg/L). Tigecycline has been used in mainland of China since 2011 but has not been included in the list of State Basic Drugs for Medical Insurance; however, clinical application is increasingly wide. Our data showed that the MIC~90~ value of tigecycline was 4 mg/L for *A. baumannii*, which was higher than that reported for the monitoring data in 2005--2011 by Denys *et al*. (MIC~90~ 1--2 mg/L).\[[@ref7]\] The breakpoint of tigecycline has not been established.

Prolonged hospitalization, ICU stays, invasive medical procedures, and prior broad-spectrum antibiotic use, especially carbapenems, third-generation cephalosporins, and fluoroquinolones, have been shown to be risk factors for the acquisition of IRAB and MDR infections.\[[@ref13][@ref14][@ref15][@ref16][@ref17][@ref18]\] All these factors, as well as clonal dissemination, likely contributed to the increased prevalence of IRABC and XDRAB.\[[@ref19][@ref20][@ref21]\] In the present study, among the 2917 *A. baumannii* strains isolated, 1276 (43.7%) XDRAB strains were detected. The prevalence of XDRAB significantly increased over our study period, reaching 60.4% by 2014. The prevalence of *A. baumannii* in the eastern region of mainland China was slightly higher than that in the central and western regions. The prevalence of *A. baumannii* among non-ICU patients was higher than that in ICU patients, but the prevalence of XDRAB among ICU patients was significantly higher than that in non-ICU patients, which might be related to the severity of patients' conditions and therefore the use of more broad-spectrum antibiotics, especially carbapenems in ICU patients. The prevalence of XDRAB in respiratory specimens accounts for more than 60% of the total, followed by chest and abdominal drainage fluids, cerebrospinal fluid, and blood specimens. The prevalence of XDRAB among different specimens also showed an increasing trend over the study period. It should be noted, however, that for pneumonia and infections of other nonsterile sites, it is often difficult to distinguish colonization from real *A. baumannii* infections and to determine to which type of pathogen therapy should be directed.\[[@ref19]\] Therefore, some of the epidemiological source data may include isolates that were not responsible for the primary infections, but were simply colonizing ill patients, and the estimate of resistance may consequently show some bias.

In this study, samples were only collected from some of the tertiary hospitals in the eastern, central, and western regions of mainland China. Coverage is therefore limited, and our data may not therefore be completely representative of the overall state of bacterial resistance in mainland China. However, the MICs of all clinical isolates were determined in this study which more accurately reflects the sensitivity of bacteria to antimicrobial agents compared with the K-B method sensitivity test.

This longitudinal multicenter surveillance program revealed the significantly increased prevalence and nationwide emergence of IRAB and XDRAB in mainland China, despite the fact that nonsusceptibility to other antibiotics remained stable or declined over the past 10 years. Given the increase in carbapenem resistance over the last decade, this once-reliable drug class now offers only slightly better than 30% coverage of this pathogen. *a priori* prediction of resistance is difficult as *A. baumannii* has multiple related mechanisms of resistance. However, if carbapenem resistance continues to increase in *A. baumannii*, empiric coverage for carbapenem-resistant and XDR strains will likely require colistin-based combination therapy even prior to the determination of antimicrobial susceptibilities in critically ill patients.

In conclusion, we hope that this study provides insight into the situation regarding the antimicrobial resistance of *A. baumannii* as well as the currently available treatment options, thereby leading to new strategies to combat *A. baumannii*.
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